News

November 1, 2017November 1, 2017

Propanc Biopharma Seeks Orphan Drug Status for PRP, Its Lead Product for Ovarian Cancer Treatment

News

Propanc Biopharma has submitted an orphan drug designation request to the U.S. Food and Drug Administration (FDA) for PRP, its lead product for treatment of ovarian cancer. PRP is an intravenous ... Read more

October 30, 2017

Small RNA Molecules Are Ancient Kill Switches that Cause Cancer Cell Death, Study Reveals

News

A recent study reports that small RNA molecules, siRNAs and shRNAs, may contain sequences that simultaneously target multiple survival genes, which ultimately causes efficient cancer cell death. This discovery, eight ... Read more

October 27, 2017

FDA to Review Genentech’s Avastin as Front-line Treatment for Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration has accepted for review Genentech‘s supplemental Biologics License Application (sBLA) seeking the approval of Avastin (bevacizumab) in combination with chemotherapy, as a front-line treatment for ... Read more

October 25, 2017

ICER Report Concludes Comparative Value of PARP Inhibitors is Lacking

News

The Institute for Clinical and Economic Review (ICER), an independent body that assesses the value of drugs newly approved by the U.S. Food and Drug Administration, confirmed that evidence is ... Read more

October 23, 2017

Oncbiomune to Advance Ovarian Cancer Vaccine into Clinical Trials

News

OncBioMune Pharmaceuticals is advancing its investigative ovarian cancer vaccine OvcaVax into human clinical trials to test its safety and efficacy in the adjuvant (after surgery) setting. OncBioMune announced it will meet in ... Read more

October 20, 2017October 21, 2017

Ovarian Cancer Gene Therapy Specialist Is One of Three Researchers Sharing $1.3 Million in Grants

News

Three American scientists are sharing $1.3 million from the Alliance for Cancer Gene Therapy to investigate whether immunotherapy and gene therapy can combat three of the most life-threatening forms of cancer: ... Read more

October 18, 2017

Tinostamustine Enters Phase 1/2 Trial to Treat Ovarian Cancer, Other Solid Tumors

News

The investigational medicine tinostamustine (EDO-S101), developed by Mundipharma EDO GmbH, is now being tested in patients with advanced solid tumors, including ovarian cancer, in a first-in-human Phase 1/2 clinical trial. ... Read more

October 16, 2017October 16, 2017

First Patient Enrolled in NanoPac Trial Evaluating New Anti-Cancer Treatment Delivery

News

The pharmaceutical development company NanOlogy has enrolled the first participant in its Phase 2 trial evaluating the safety and effectiveness of NanoPac, a new delivery method for the anti-cancer treatment ... Read more

October 13, 2017October 13, 2017

Swansea University Researchers Win Award for Innovative Ovarian Cancer Diagnostic Test

News

An international research team at Swansea University Medical School and the university’s Centre for NanoHealth in the United Kingdom has received an international award for developing a graphene biosensor-based diagnostic ... Read more

October 11, 2017December 8, 2017

Clovis Seeks FDA Approval for Rubraca as Ovarian Cancer Maintenance Therapy

News

Clovis Oncology seeks to expand its approval for Rubraca (rucaparib) to include maintenance therapy for women with recurrent ovarian cancer who respond to platinum-based chemotherapy. The company, based in Boulder, ... Read more